The FDA revises requirements for levothyroxine products

被引：10

|

作者：

Burman, Kenneth ^{[1
,2
]}

Hennessey, James ^{[3
]}

McDermott, Michael ^{[4
]}

Wartofsky, Leonard ^{[1
,2
]}

Emerson, Charles ^{[5
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

[2] Univ Hlth Sci, Bethesda, MD USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Univ Colorado, Denver, CO 80202 USA

[5] Univ Massachusetts, Worcester, MA 01605 USA

来源：

THYROID | 2008年 / 18卷 / 05期

关键词：

D O I：

10.1089/thy.2008.0109

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：487 / 490

页数：4

相关论文

共 50 条

[21] US FDA revises prescription drug information format
Reactions Weekly, 2006, 1086 (1) : 3 - 3
[22] US FDA revises safety advice on albumin administration
Reactions Weekly, 2005, 1054 (1) : 3 - 3
[23] FDA revises drug. review nomenclature, process
不详
FORMULARY, 2004, 39 (09) : 461 - 461
[24] FDA revises guidance related to veterinary feed directive
不详
JOURNAL OF SWINE HEALTH AND PRODUCTION, 2009, 17 (04): : 227 - 227
[25] ABO revises case Category #2 requirements
不详
AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2001, 120 (02) : 227 - 227
[26] The Joint Commission revises requirements for THKR program
不详
AORN JOURNAL, 2018, 108 (03) : P6 - P6
[27] OPS revises pipeline spill reporting requirements
不详
PIPELINE & GAS JOURNAL, 2001, 228 (05) : 6 - 6
[28] SUBSTITUTION OF LEVOTHYROXINE PRODUCTS
STOFFER, SS
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1979, 241 (12): : 1229 - 1229
[29] THE NONEQUIVALENCE OF LEVOTHYROXINE PRODUCTS
DONG, BJ
YOUNG, VR
RAPOPORT, B
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1986, 20 (01): : 77 - 78
[30] POTENCY OF LEVOTHYROXINE PRODUCTS
STOFFER, SS
SZPUNAR, WE
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (05): : 635 - 636

← 1 2 3 4 5 →